[Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients].

Autor:	Amblard MA; Centre ophtalmologique Place de l'Étoile, Luxembourg., Costantini E; Centre ophtalmologique Place de l'Étoile, Luxembourg; Centre laser Monterey, Luxembourg., Hayek G; Centre ophtalmologique Place de l'Étoile, Luxembourg., Ricaud X; Centre ophtalmologique Place de l'Étoile, Luxembourg; Centre laser Monterey, Luxembourg. Electronic address: docteur.ricaud@gmail.com.
Jazyk:	francouzština
Zdroj:	Journal francais d'ophtalmologie [J Fr Ophtalmol] 2022 Nov; Vol. 45 (9), pp. 1000-1003. Date of Electronic Publication: 2022 Sep 23.
DOI:	10.1016/j.jfo.2022.09.004
Abstrakt:	Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO). (Copyright © 2022. Published by Elsevier Masson SAS.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu